SCOTTSDALE, Ariz., Nov. 18, 2010 /PRNewswire/ — Cayenne
Medical, Inc., a private sports medicine device company, announces
that it has reached its 50,000 implant milestone.
Specializing in the soft tissue segment, Cayenne currently
offers products that address previously unmet clinical needs in
knee ligament reconstruction and meniscal repair, including the
AperFix® System, CrossFix™ Meniscal Repair System and
iFix™ System. The announcement was made today at the
Arthroscopy Association of North America (AANA) 29th Fall Course in
Phoenix, AZ.
“Our 50,000th implant represents an important milestone for
Cayenne as it affirms the company’s commitment to transform the
soft tissue reconstruction segment and is proof-positive that our
technology platform continues to gain significant traction
throughout the orthopedic industry,” said James W. Hart, President
and CEO of Cayenne Medical. “We plan to continue providing
innovative sports medicine solutions that offer ease-of-use for
physicians and improve quality of life for patients looking to
continue their active lifestyles.”
The company’s flagship product AperFix is a stronger, less
invasive femoral and tibial fixation device for soft tissue
multi-ligament repair, including the most common anterior cruciate
ligament (ACL) and posterior cruciate ligament (PCL) tears.
First implanted in the United States three years ago, the
AperFix technology has been used by more than 1,300 surgeons in 20
countries.
The AperFix single tunnel, all-inside surgical technique
attaches a soft tissue graft at the aperture (opening) of the
femoral and tibial tunnels created for fixation. This creates
a shorter, stiffer and more anatomic ligament reconstruction that
is designed to restore natural knee kinematics. For ACL
reconstruction, the technically less-demanding procedure can be
performed using a traditional tibial approach or a more anatomical
approach through the
‘/>”/>
